Patents by Inventor Kerstin Kapp

Kerstin Kapp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING A LATENT HIV-1 INFECTION USING NON-CODING DEOXYRIBONUCLEIC ACIDS
    Publication number: 20230310594
    Abstract: The invention relates to a non-coding sequence of deoxyribonucleic acids comprising at least one sequence motif N1N2CGN3N4, wherein N is a nucleotide comprising A, C, T, or G, and C is deoxycytidine, G is deoxyguanosine, A is deoxyadenosine and T is deoxythymidine for the treatment of viral infections. In particular, the non-coding sequence of deoxyribonucleic acids is used in combination with antiretroviral therapy and/or histone de-acetylase inhibitors.
    Type: Application
    Filed: January 11, 2023
    Publication date: October 5, 2023
    Inventors: Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Alfredo Zurlo, Ole Schmeltz Sogaard, Martin Tolstrup, Rasmus Offersen
  • Methods of treating a retroviral infection
    Patent number: 11583581
    Abstract: The invention relates to a non-coding sequence of deoxyribonucleic acids comprising at least one sequence motif N1N2CGN3N4, wherein N is a nucleotide comprising A, C, T, or G, and C is deoxycytidine, G is deoxyguanosine, A is deoxyadenosine and T is deoxy-thymidine for the treatment of viral infections. In particular, the non-coding sequence of deoxyribonucleic acids is used in combination with antiretroviral therapy and/or histone de-acetylase inhibitors.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: February 21, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Alfredo Zurlo, Ole Schmeltz Sogaard, Martin Tolstrup, Rasmus Offersen
  • Combination comprising immunostimulatory oligonucleotides
    Patent number: 11578331
    Abstract: The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAG3, CD137(4-1BB) and a non-coding immunomodulating DNA.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: February 14, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Alfredo Zurlo
  • NON-CODING IMMUNOMODULATORY DNA CONSTRUCT
    Publication number: 20210340543
    Abstract: The present invention relates to a nucleic acid molecule and its use for the modulation of the immune system. It provides a DNA construct for immunomodulation comprising at least one nucleotide in L-conformation.
    Type: Application
    Filed: September 11, 2020
    Publication date: November 4, 2021
    Inventors: Matthias SCHROFF, Christiane KLEUSS, Kerstin KAPP
  • TLR-9 AGONISTS FOR MODULATION OF TUMOR MICROENVIRONMENT
    Publication number: 20210155933
    Abstract: A TLR-9 agonist for use in the treatment of a tumor disease, in particular of colon cancer, and for the modulation of the tumor microenvironment.
    Type: Application
    Filed: August 31, 2018
    Publication date: May 27, 2021
    Inventors: Manuel SCHMIDT, Kerstin KAPP
  • TLR-9 AGONISTS FOR MODULATION OF TUMOR MICROENVIRONMENT
    Publication number: 20210079403
    Abstract: A TLR-9 agonist for use in the treatment of a tumor disease, in particular of colon cancer, and for the modulation of the tumor microenvironment.
    Type: Application
    Filed: August 31, 2018
    Publication date: March 18, 2021
    Applicant: Mologen AG
    Inventors: Manuel SCHMIDT, Kerstin KAPP
  • Combination comprising immunostimulatory oligonucleotides
    Publication number: 20210010003
    Abstract: The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAG3, CD137(4-1BB) and a non-coding immunomodulating DNA.
    Type: Application
    Filed: February 18, 2020
    Publication date: January 14, 2021
    Applicant: Mologen AG
    Inventors: Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Alfredo Zurlo
  • BIOMARKER FOR SMALL CELL LUNG CANCER THERAPY
    Publication number: 20200385732
    Abstract: A TLR-9 agonist provided for use in treating small cell lung cancer (SCLC) in a subject in need thereof, wherein the subject to be treated has a low level of activated B cells and/or is diagnosed with chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: April 23, 2018
    Publication date: December 10, 2020
    Applicant: Mologen AG
    Inventors: Manuel SCHMIDT, Kerstin KAPP, Maxim KRIKOV, Burghardt WITTIG
  • MEANS FOR THE TREATMENT OF HIV
    Publication number: 20200230234
    Abstract: The invention relates to a non-coding sequence of deoxyribonucleic acids comprising at least one sequence motif N1N2CGN3N4, wherein N is a nucleotide comprising A, C, T, or G, and C is deoxycytidine, G is deoxyguanosine, A is deoxyadenosine and T is deoxy-thymidine for the treatment of viral infections. In particular, the non-coding sequence of deoxyribonucleic acids is used in combination with antiretroviral therapy and/or histone de-acetylase inhibitors.
    Type: Application
    Filed: September 21, 2016
    Publication date: July 23, 2020
    Applicant: MOLOGEN AG
    Inventors: Matthias SCHROFF, Manuel SCHMIDT, Kerstin KAPP, Alfredo ZURLO, Ole SCHMELTZ SOGAARD, Martin TOLSTRUP, Rasmus OFFERSEN
  • Combination comprising immunostimulatory oligonucleotides
    Patent number: 10604760
    Abstract: The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAGS, CD137(4-1BB) and a non-codiung immuno-modulating DNA.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: March 31, 2020
    Assignee: Mologen AG
    Inventors: Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Alfredo Zurlo
  • Combination comprising immunostimulatory oligonucleotides
    Patent number: 10487333
    Abstract: The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAG3, CD137(4-1BB) and a non-coding immunomodulating DNA.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: November 26, 2019
    Assignee: Mologen AG
    Inventors: Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Alfredo Zurlo
  • COMBINATION COMPRISING IMMUNOSTIMULATORY OLIGONUCLEOTIDES
    Publication number: 20190316134
    Abstract: The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAGS, CD137(4-1BB) and a non-codiung immuno-modulating DNA.
    Type: Application
    Filed: June 26, 2019
    Publication date: October 17, 2019
    Applicant: Mologen AG
    Inventors: Matthias SCHROFF, Manuel SCHMIDT, Kerstin KAPP, Alfredo ZURLO
  • Covalently closed non-coding immunomodulatory DNA construct
    Patent number: 10280424
    Abstract: The present invention relates to a covalently closed DNA construct, a pharmaceutical composition and a vaccine and their use for the modulation of the immune system. It provides a DNA construct for immunomodulation comprising a specific DNA sequence.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: May 7, 2019
    Assignee: Mologen AG
    Inventors: Christiane Kleuss, Kerstin Kapp, Burghardt Wittig, Matthias Schroff
  • COMBINATION COMPRISING IMMUNOSTIMULATORY OLIGONUCLEOTIDES
    Publication number: 20180251767
    Abstract: The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAG3, CD137(4-1BB) and a non-coding immunomodulating DNA.
    Type: Application
    Filed: September 9, 2016
    Publication date: September 6, 2018
    Applicant: MOLOGEN AG
    Inventors: Matthias SCHROFF, Manuel SCHMIDT, Kerstin KAPP, Alfredo ZURLO
  • Predictive biomarker for cancer therapy
    Patent number: 10006032
    Abstract: The present invention relates generally to the identification of patients suffering from cancer whether they will respond to specific therapies. More particularly the invention relates to a method and means for identifying responder to a therapy TLR-9 agonists.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: June 26, 2018
    Assignee: Mologen AG
    Inventors: Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Burghardt Wittig
  • Covalently closed non-coding immunomodulatory DNA construct
    Publication number: 20160348114
    Abstract: The present invention relates to a covalently closed DNA construct, a pharmaceutical composition and a vaccine and their use for the modulation of the immune system. It provides a DNA construct for immunomodulation comprising a specific DNA sequence.
    Type: Application
    Filed: February 18, 2015
    Publication date: December 1, 2016
    Inventors: Christiane Kleuss, Kerstin Kapp, Burghardt Wittig, Matthias Schroff
  • Predictive Biomarker for Cancer Therapy
    Publication number: 20160115479
    Abstract: The present invention relates generally to the identification of patients suffering from cancer whether they will respond to specific therapies. More particularly the invention relates to a method and means for identifying responder to a therapy TLR-9 agonists.
    Type: Application
    Filed: May 15, 2014
    Publication date: April 28, 2016
    Inventors: Matthias Schroff, Manuel Schmidt, Kerstin Kapp, Burghardt Wittig
  • Non-Coding Immunomodulatory DNA Construct
    Publication number: 20140010830
    Abstract: The present invention relates to a nucleic acid molecule and its use for the modulation of the immune system. It provides a DNA construct for immunomodulation comprising at least one nucleotide in L-conformation.
    Type: Application
    Filed: December 23, 2011
    Publication date: January 9, 2014
    Applicant: MOLOGEN AG
    Inventors: Matthias Schroff, Christiane Kleuss, Kerstin Kapp
  • DNA Expression Construct
    Publication number: 20130287814
    Abstract: The invention relates to a minimalistic gene expression construct, its transfer into cells and its use for gene expression for molecular-medical applications. According to the disclosure, a DNA construct for gene expression is provided, wherein the construct is a linear and open-chained DNA double strand comprising a promoter sequence, a coding sequence and a termination signal, wherein the construct comprises at least one L-DNA nucleotide.
    Type: Application
    Filed: December 23, 2011
    Publication date: October 31, 2013
    Inventors: Matthias Schroff, Christiane Kleuss, Kerstin Kapp